Embed

Academic

Authors

Antoine Yver

Antoine Yver,University of Oxford,Oncology,Pharmacology,Virology

Edit

Antoine Yver

University of Oxford

Publications: 14 | Citations: 237

Fields: Oncology, Pharmacology, Virology

Collaborated with 1776 co-authors from 1991 to 2011 | Cited by 1127 authors

Cumulative Annual

Sort by:

Publications (14)

BibTeX | RIS | RefWorks Download

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

, , , , , , , , ,

Journal: Cancer Chemotherapy and Pharmacology - CANCER CHEMOTHER PHARMACOL , vol. 67, no. 3, pp. 657-666, 2011

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

, , , , , ,

Journal: Cancer Chemotherapy and Pharmacology - CANCER CHEMOTHER PHARMACOL , vol. 65, no. 4, pp. 671-677, 2010

Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - a comparative study (Citations: 19)

, , , , , ,

Journal: European Journal of Haematology - EUR J HAEMATOL , vol. 59, no. 3, pp. 177-183, 2009

Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study (Citations: 13)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=30774326&selfId1=25264240&selfId2=0&maxNumber=12&query=

Journal: Journal of Clinical Oncology - J CLIN ONCOL , vol. 25, no. 21, pp. 3137-3143, 2007

Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil???cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck (Citations: 21)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=32152626&selfId1=25264240&selfId2=0&maxNumber=12&query=

Journal: Anti-cancer Drugs - ANTI-CANCER DRUG , vol. 15, no. 4, pp. 331-340, 2004

Sort by:

Citations (237 times by 235 publications)

Melanoma in 2011A new paradigm tumor for drug development

Journal: Nature Reviews Clinical Oncology - NAT REV CLIN ONCOL , vol. 9, no. 2, pp. 74-76, 2012

Development and Utility of an Internal Threshold Control (ITC) Real-Time PCR Assay for Exogenous DNA Detection

, , ,

Journal: PLOS One , vol. 7, no. 5, 2012

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors (Citations: 1)

, , , , , , , , ,

Journal: Cancer Chemotherapy and Pharmacology - CANCER CHEMOTHER PHARMACOL , vol. 67, no. 2, pp. 455-463, 2011

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)

, , , , , , , , , ,

Journal: Clinical & Translational Oncology - CLIN TRANSL ONCOL , vol. 13, no. 4, pp. 254-260, 2011

Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradio therapy for Organ Preservation in Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue

, , , , , , , ,

Journal: Strahlentherapie Und Onkologie - STRAHLENTHER ONKOL , vol. 187, no. 1, pp. 15-22, 2011

Comments

Co-authors (1776)

Journals (12)

Keywords (43)

Antoine Yver,University of Oxford,Oncology,Pharmacology,Virology

Publications (14)

BibTeX | RIS | RefWorks Download

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - a comparative study (Citations: 19)

Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study (Citations: 13)

Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil???cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck (Citations: 21)

Citations (237 times by 235 publications)

Melanoma in 2011A new paradigm tumor for drug development

Development and Utility of an Internal Threshold Control (ITC) Real-Time PCR Assay for Exogenous DNA Detection

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors (Citations: 1)

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)

Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradio therapy for Organ Preservation in Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue


	View FAQ about top research areas and Fields of study

Antoine Yver,University of Oxford,Oncology,Pharmacology,Virology

Publications (14) BibTeX | RIS | RefWorks Download

Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - a comparative study (Citations: 19)

Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study (Citations: 13)

Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil???cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck (Citations: 21)

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors (Citations: 1)

Publications (14)

BibTeX | RIS | RefWorks Download